knowledge -WSS

knowledge

author：focus 2025-09-29 01:35:19 - browse：55759

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： CVS is on a mission to consolidate health care. Will it work?

focus

knowledge

WSS

Flu vaccine reformulation won't be easy, manufacturers warn

Dewpoint Therapeutics lays off staff after losing partnerships

Eli Lilly, Pfizer, and others want in on the online prescription market

My yearlong odyssey to get my son’s ADHD medication covered

How digital therapeutics firms are pivoting after Pear's bankruptcy

Copay coupons to count toward deductibles, after Biden court move

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Sports medicine is finally prioritizing gender equality

Microsoft launches AI tool for clinical documentation through Epic

Continuity nursing helped my family in our darkest PICU moments

Head of FDA's diagnostics center, who led through Covid, retires

Tori Bowie and the unacceptable rates of Black maternal death

Printout prescription drug information shouldn’t go digital

23andMe had bad news about my health. I wish a person had delivered it

Future doctors need a strong humanities education

Jerome Adams on the need for new antivirals for Covid

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

focus

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Humana cuts profit projections as Medicare Advantage costs soar

CVS is on a mission to consolidate health care. Will it work?

Mass General, Mayo Clinic look to monetize custom

CVS is on a mission to consolidate health care. Will it work?

Mass General, Mayo Clinic look to monetize custom

Wikipedia

focus

knowledge

focus